Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

By M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot and 10 more. Journal of Clinical Oncology, 2009

1,280 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/ce0c9948f444c9fc94a2543847505f3c4a7e64f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Brian J. Druker
2. J. Cortes
3. J. Goldman
4. J. Apperley
5. Andreas Hochhaus
6. H. Kantarjian
7. M. Baccarani

In Rheumatology

1. Brian J. Druker
2. J. Cortes
3. Andreas Hochhaus
4. H. Kantarjian
5. M. Baccarani

Citations in the corpus

• Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, background): “(defined as a major molecular response [MMR])(3); this confers additional clinical benefit,(5) and it is also considered an important therapeutic target.(6) With continued treatment, approximately 20% to 30% of patients eventually achieve a 4-log reduction; in at least 10% of patients, the transcrip”
• Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012, background): “8,23 In addition, patients were required to be at least 18 years old and to have an Eastern Cooperative Oncology Group performance status of 2 or lower (on a scale ranging from 0 to 5, where 0 indicates that the patient is fully active and higher numbers indicate increasing disability) 24 and…”
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, methodology): “The definitions of chronic phase (CP), accelerated phase (AP), and blastic phase (BP) (Table 1) were unchanged from prior published versions.(4,5) For treatment-naı̈ve CP patients, 3 risk scores were analyzed (Table 2): Sokal, Euro, and EUTOS.”